Request Info

Prescient Therapeutics


  • Prescient Therapeutics is developing drugs to treat a range of cancers with significant unmet need. Prescient has one of the deepest clinical pipelines on the ASX, with two drugs that turn off “master switches” that are known to drive cancer.
  • Exciting interim breast cancer data for PTX-200 has exhibited twice the effectiveness of standard therapy. A new transformative trial for PTX-100 will also soon commence.